Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Market Closed 07-10 16:00:00 EDT

4.28

+0.15

+3.63%

盘后4.18

-0.10-2.34%

19:25 EDT

High4.32	Low3.85	Vol3.45M
Open4.12	D1 Closing4.13	Amplitude11.38%
Mkt Cap445.12M	Tradable Cap254.62M	Total Shares104.00M
T/O14.24M	T/O Rate5.79%	Tradable Shares59.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":4.28,"timestamp":1783713600000,"preClose":4.13,"halted":0,"volume":3445587,"hourTrading":{"tag":"盘后","latestPrice":4.18,"preClose":4.28,"latestTime":"19:25 EDT","volume":10633,"amount":45290.022,"timestamp":1783725919686,"change":-0.1,"changeRate":-0.023364,"amplitude":0.027243},"delay":0,"changeRate":0.03631961259079912,"floatShares":59489900,"shares":104000000,"eps":-2.08756,"marketStatus":"Market Closed","change":0.15,"latestTime":"07-10 16:00:00 EDT","open":4.12,"high":4.32,"low":3.85,"amount":14237170.307821801,"amplitude":0.113801,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.08756,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":4.13,"preHourTrading":{"tag":"盘前","latestPrice":4.13,"preClose":4.13,"latestTime":"09:24 EDT","volume":5308,"amount":22077.686483999998,"timestamp":1783689867011,"change":0,"changeRate":0,"amplitude":0.084746},"postHourTrading":{"tag":"盘后","latestPrice":4.18,"preClose":4.28,"latestTime":"19:25 EDT","volume":10633,"amount":45290.022,"timestamp":1783725919686,"change":-0.1,"changeRate":-0.023364,"amplitude":0.027243},"volumeRatio":1.4569885265571123,"impliedVol":1.923,"impliedVolPercentile":0.4741},"requestUrl":"/m/hq/s/LRMR/tweets","defaultTab":"tweets","newsList":[{"id":"2650748915","title":"Larimar Therapeutics director buys $167K in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2650748915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650748915?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:10","pubTimestamp":1783541411,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Larimar Therapeutics (LRMR) disclosed that its director, Thomas Hamilton, bought 50,000 shares of common stock on July 6th ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LRMR","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650903915","title":"Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650903915","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650903915?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:06","pubTimestamp":1783541177,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics director Thomas Edward Hamilton acquires USD 166,890 of common sharesLarimar Therapeutics director Thomas Edward Hamilton bought 50,000 common shares at a weighted-average price o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL16NRLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648696779","title":"Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2648696779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648696779?lang=en_us&edition=fundamental","pubTime":"2026-07-04 17:02","pubTimestamp":1783155759,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($ADBE) ), ( ($LRMR) ), ( ($PLTR) ), ( ($CVX) ) and ( ($AGNT) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/adobe-larimar-palantir-chevron-exp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/adobe-larimar-palantir-chevron-exp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLTU","LU0957791311.USD","LU0300736062.USD","LU0417517546.SGD","LU2458330243.SGD","BK4566","LU0070302665.USD","LU1803068979.SGD","LU0472753341.HKD","LU0106261372.USD","LU0557290698.USD","GUNZ","LU1066051498.USD","SHLD","LU1861559042.SGD","LU0672654240.SGD","DIG","IE00BQXX3C00.GBP","LU2237438978.USD","LU0198837287.USD","LU1496350502.SGD","LU2210149790.SGD","LU0965509283.SGD","IE00B19Z3B42.SGD","LU1267930813.SGD","LU1430594728.SGD","LU2168564222.USD","LU1162221912.USD","LU2129689605.HKD","LU2089283258.USD","IE00B19Z9505.USD","LU0158827948.USD","LU0345780950.USD","IE00BYQQ9H92.USD","LU0098860793.USD","LU1235294995.USD","LU1496350171.SGD","LU2023251221.USD","DRLL","LU0345770993.USD","IE00B5TLWC47.USD","XLE","IE00B2Q91V27.USD","IE00B894F039.SGD","CVX","LU2125154778.USD","PLTY","LU1366333091.USD","BK4585","LU0234570918.USD","LU1261432733.SGD","LU0157215616.USD","LU1119994496.HKD","PLTD","LU0109392836.USD","LU1861558580.USD","PLTR","LU0122376428.USD","LU0348723411.USD","LU0057025933.USD","LU2357305700.SGD","LU1084165304.USD","BK4588","LU0061474960.USD","LU0109391861.USD","BK4567","LU0320765489.SGD","PLT","PLTA","BK4139","LU0006306889.USD","LU1116320901.HKD","LU0861579265.USD","LU2095319765.USD","IE00B19Z9P08.USD","LU2125154935.USD","SG9999000418.SGD","LU0456854461.SGD","LU1623119135.USD","LU0149725797.USD","LU2168563687.JPY","LU0320765059.SGD","LU0345781412.USD","BK4581","LU2381873111.SGD","LU1815333072.USD","LU2168564149.EUR","IE000M9KFDE8.USD","LU0345770308.USD","FENY","LU0368265418.SGD","WEEI","AIPI","LU1929549753.HKD","SGXZ81514606.USD","LU0965509010.AUD","LU2236285917.USD","LU1712237335.SGD","BK4592","LRMR","LU0234572021.USD","LU0342679015.USD","LU0345774631.USD","LU0965509101.SGD","LU0868494708.USD","LU0265550946.USD","LU0889565833.HKD","LU0788109394.HKD","LU0612318385.USD","LU0868494617.USD","IE00B19Z3581.USD","BK4201","BK4527","IE00BQXX3F31.USD","IXC","LU0708995401.HKD","LU1585245621.USD","IE0009356076.USD","PLTG","BK4543","IE00B7SZLL34.SGD","BK4559","IE00B3CCJ963.GBP","LU0289739343.SGD","LU0081259029.USD","SGXZ99366536.SGD","PLTW","LU0208291251.USD","LU1548497426.USD","LU0889566641.SGD","LU1720051108.HKD","IE00BQXX3D17.EUR","LU0719512351.SGD","LU0630314457.HKD","PLTZ","LU1074936037.SGD","PTIR","LU0069063385.USD","LU2360032135.SGD","PLOO","LU0345774391.USD","SGXZ51526630.SGD","IE00BGHQF524.EUR","IE00BZ9MQY76.HKD","LU0256863811.USD","LU2129689431.USD","LU2133065610.SGD","ADBG","LU2210150020.SGD","BK4613","LU0640476718.USD","LU0170899867.USD","LU0942090050.USD","LU0511384066.AUD","PLTI","SG9999002521.SGD","LU0289961442.SGD","LU1674673428.USD","ADBE","LU0320765646.SGD","LU1691799644.USD","LU1823568750.SGD","IE00BFXG0V08.USD","LU0278409577.USD","LU1633808545.USD","LU0314104364.USD","BK4023","LU2129689514.USD","LU0082616367.USD","SG9999001424.SGD","LU0612318971.USD","PLYY","BK4550","BK4547","LU0792757196.USD","BK4528","LU0300736492.USD","FTXN","LU1116320737.USD","IGE","BK4534","LU1778281490.HKD","LU2089284900.SGD","LU2168564495.EUR","LU2317271919.USD","BK4554","LU1674673691.USD","LU2168564065.EUR","LU0654597011.USD","LU0266512127.USD","LU1066053197.SGD","IE00B19Z9Z06.USD","BK4533","IE0002270589.USD","LU0265550359.USD","IYE","IGV","VDE","LU2458330169.SGD","LU1430597077.USD","ERX","BK4570","LU1267930730.SGD","LU1280957306.USD","LU1720051017.SGD","LU1046421795.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537101","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537101?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:40","pubTimestamp":1782816035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR) and Arrowhead Pharmaceut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-238?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-238?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647420534","title":"Larimar Therapeutics selloff a buying opportunity, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2647420534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647420534?lang=en_us&edition=fundamental","pubTime":"2026-06-30 17:55","pubTimestamp":1782813321,"startTime":"0","endTime":"0","summary":"Citi recommends buying Larimar Therapeutics (LRMR) shares on yesterday’s weakness. FDA feedback indicates the company’s current data package is suf...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU","LENZ","LRMR","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647930511","title":"Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2647930511","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647930511?lang=en_us&edition=fundamental","pubTime":"2026-06-30 00:15","pubTimestamp":1782749742,"startTime":"0","endTime":"0","summary":"In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics, with a price target of $25.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nomlabofusp-progress-and-durable-efficacy-support-buy-rating-on-lrmr-with-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nomlabofusp-progress-and-durable-efficacy-support-buy-rating-on-lrmr-with-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647036370","title":"Larimar stumbles on safety news even as BLA submission kicks off","url":"https://stock-news.laohu8.com/highlight/detail?id=2647036370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647036370?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:25","pubTimestamp":1782743113,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) shares slid on Monday after the company reported new safety findings from its open label study of nomlabofusp for Fried...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-stumbles-on-safety-news-even-as-bla-submission-kicks-off-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-stumbles-on-safety-news-even-as-bla-submission-kicks-off-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647137183","title":"Larimar Tumbles as Safety Concerns Resurface in Rare Disease Drug Study Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2647137183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647137183?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:14","pubTimestamp":1782735246,"startTime":"0","endTime":"0","summary":"BUZZ-Larimar tumbles as safety concerns resurface in rare disease drug study update** Larimar Therapeutics'LRMR.Oshares fall 22.2% to $2.84 premarket** LRMR has begun rolling submission for acceleratedU.S. FDAapproval of its drug nomlabofusp, a daily injection for Friedreich's ataxia, a rare and progressive nerve disease**Company says FDAhas signaled that LRMR's existing data sufficient to support a full review, with a potential mid-2027 launch, if approved** Larimar reported cases of anaphylaxis in its latest study update, after similarsafety concernsflagged last year** Ten of 43 patients experienced anaphylaxis, a sudden and severe allergic reaction that can cause breathing problems, swelling and a drop in blood pressure** Long-term study data shows patients on the drug for one year improved protein levels and signs of clinical benefit** Company saysabout 21 of the 43 patientsin the ongoing study have dropped out** As of last close, stock down ~4% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N4310YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037629","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037629","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647037629?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:37","pubTimestamp":1782733022,"startTime":"0","endTime":"0","summary":"Farmmi  shares were down 68% in Monday premarket activity after the company announced a public offering of Class A ordinary shares.Jupiter Neurosciences  stock was down 22% after the company filed a prospectus for the resale of up to 16 million shares.Creative Realities  shares were down 19% after the company launched a public offering of common shares and pre-funded warrants.Larimar Therapeutics  stock was down 16%, following the previous session's 4.6% gain.PicoCELA  shares were down 16% after the previous session's 127% gain.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CREX","FAMI","BK4009","PCLA","LRMR","BK4020","BK4212","BK4007","BK4139","JUNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647737813","title":"Larimar Therapeutics submits first module of rolling BLA for nomlabofusp","url":"https://stock-news.laohu8.com/highlight/detail?id=2647737813","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647737813?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:35","pubTimestamp":1782729306,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) announced it has submitted the first module of its rolling Biologics License Application submission to the FDA for acce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-submits-first-module-of-rolling-bla-for-nomlabofusp-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-submits-first-module-of-rolling-bla-for-nomlabofusp-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4588","BK4007","LRMR","LENZ","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647373673","title":"Larimar Therapeutics Submits First Module of Rolling BLA to FDA for Nomlabofusp in Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2647373673","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647373673?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729025,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics submits first module of rolling BLA to FDA for nomlabofusp in Friedreich’s ataxiaLarimar Therapeutics submitted the first module of a rolling BLA to the FDA for accelerated approv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9TH4d1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","LRMR","NDAQ","LU2095319765.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647837362","title":"Larimar Therapeutics - First Patient Dosing in Phase 3 Study Expected Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647837362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647837362?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA4YWZT6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647373936","title":"Larimar Therapeutics - Nomlabofusp Long-term Dosing Generally Well-tolerated; Anaphylaxis in 10 of 43 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2647373936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647373936?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA4YWZT6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647373933","title":"Larimar Therapeutics - Submits First Module of Rolling Bla for Nomlabofusp; Remaining Modules Expected 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647373933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647373933?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA4YWZT6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646860360","title":"Larimar Therapeutics to Host Investor Webcast on Nomlabofusp Program for Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2646860360","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646860360?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:05","pubTimestamp":1782504327,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics to host investor webcast on nomlabofusp program for Friedreich’s ataxiaLarimar Therapeutics will host an investor webcast on June 29, 2026, at 7:45 a.m. ET.Event will cover a regu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL2l4RWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU0314104364.USD","LU2095319765.USD","BK4112","IE00BN0W2W23.USD","BK4139","SG9999014039.USD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LRMR","LU2210150020.SGD","NDAQ","SG9999014021.USD","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638168895","title":"U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys","url":"https://stock-news.laohu8.com/highlight/detail?id=2638168895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638168895?lang=en_us&edition=fundamental","pubTime":"2026-05-27 16:06","pubTimestamp":1779869170,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, SynopsysMay 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agile","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nL4N4240LW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2063271972.USD","ACNB","GE","AGCO","APLD","PANW","VRRM","LW","AZO","CVX","IE0031619046.USD","AR","VICR","KNX","AMAT","CI","CNC","PALU","SKY","PTC","SNPX","APLZ","SNPS","AAL","ALHC","AALG","APA","FDX","PALD","CRK","APLX","CNCG","ZS","AGL","ASTH","BURL","LRMR","SMTC","PANG","ET","PODD","CDNS","BXP","ALK","IPSC","A","ELF","MO","APGE","CRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638575625","title":"Larimar Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2638575625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638575625?lang=en_us&edition=fundamental","pubTime":"2026-05-27 12:35","pubTimestamp":1779856518,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4230D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636268864","title":"Larimar Therapeutics shareholders approve increase in authorized common shares to 215 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636268864","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636268864?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:30","pubTimestamp":1779222622,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics held its annual shareholder meeting on May 19, 2026.Shareholders backed an amendment to the company’s certificate of incorporation to raise authorized common stock to 215,000,000 shares from 115,000,000.Shareholders elected a one-year cadence for future advisory votes on executive pay, with the board set to hold those votes annually until the next required frequency vote.An adjournment authority was approved as a contingency to secure enough votes for the share authorization increase, though no adjournment was needed because the amendment passed at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL23h2S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089531","title":"Exploring US High Growth Tech Stocks This May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089531","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089531?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:08","pubTimestamp":1778843301,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen by 1.1% and is up 27% over the past year, with earnings forecasted to grow by 17% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to leverage these promising conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/exploring-us-high-growth-tech-stocks-this-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/exploring-us-high-growth-tech-stocks-this-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KARO","BK4130","BK4539","BK4139","BK4613","CLBT","BK4023","FA","LRMR","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719787","title":"Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719787?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:08","pubTimestamp":1778756925,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Q1 net loss widens slightly R&D expenses fallOverviewUS rare disease biotech reported Q1 net loss and lower R&D expenses yr/yrCompany advancing nomlabofusp toward rolling BLA subm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":0.3129},{"period":"1month","weight":0.2442},{"period":"3month","weight":-0.1175},{"period":"6month","weight":0.2853},{"period":"1year","weight":0.2299},{"period":"ytd","weight":0.1234}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.088036},{"month":2,"riseRate":0.583333,"avgChangeRate":0.090114},{"month":3,"riseRate":0.25,"avgChangeRate":-0.145723},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.03405},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.096181},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004489},{"month":7,"riseRate":0.538462,"avgChangeRate":0.010743},{"month":8,"riseRate":0.5,"avgChangeRate":0.081374},{"month":9,"riseRate":0.416667,"avgChangeRate":0.000938},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.029427},{"month":11,"riseRate":0.583333,"avgChangeRate":0.038429},{"month":12,"riseRate":0.583333,"avgChangeRate":0.050649}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}